This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2022 Jul;175(7):1053-1055.

doi: 10.7326/M22-0756. Epub 2022 Jun 21.

Potential Medicare Part D Savings on Generic Drugs From the Mark Cuban Cost Plus Drug Company

Hussain S Lalani¹, Aaron S Kesselheim¹, Benjamin N Rome¹

Affiliations

Affiliation

¹ Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts.

PMID: 35724381
DOI: 10.7326/M22-0756

Potential Medicare Part D Savings on Generic Drugs From the Mark Cuban Cost Plus Drug Company

Hussain S Lalani et al. Ann Intern Med. 2022 Jul.

. 2022 Jul;175(7):1053-1055.

doi: 10.7326/M22-0756. Epub 2022 Jun 21.

Authors

Hussain S Lalani¹, Aaron S Kesselheim¹, Benjamin N Rome¹

Affiliation

¹ Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts.

PMID: 35724381
DOI: 10.7326/M22-0756

Erratum in

Correction: Potential Medicare Part D Savings on Generic Drugs From the Mark Cuban Cost Plus Drug Company.
[No authors listed] [No authors listed] Ann Intern Med. 2022 Sep;175(9):1342. doi: 10.7326/L22-0294. Epub 2022 Jul 12. Ann Intern Med. 2022. PMID: 35816714 No abstract available.

No abstract available

PubMed Disclaimer

Similar articles

Drug Pricing Stewardship from Mark Cuban's Cost Plus Generic Drug Program.
Gulati S, Gupta M, Yan T, Yelamanchili S, Xu LQ, Bharani T, Naji A, Agarwal D. Gulati S, et al. Pharmacoeconomics. 2024 Nov;42(11):1279-1286. doi: 10.1007/s40273-024-01426-3. Epub 2024 Aug 21. Pharmacoeconomics. 2024. PMID: 39167355
Projected Savings for Generic Oncology Drugs Purchased via Mark Cuban Cost Plus Drug Company Versus in Medicare.
Cortese BD, Dusetzina SB, Luckenbaugh AN, Al Hussein Al Awamlh B, Stimson CJ, Barocas DA, Penson DF, Chang SS, Talwar R. Cortese BD, et al. J Clin Oncol. 2023 Oct 10;41(29):4664-4668. doi: 10.1200/JCO.23.00079. Epub 2023 Jun 8. J Clin Oncol. 2023. PMID: 37290029
Potential Cost Savings in Medicare Part D Across Gastroenterology: An Assessment of Alternative Drug Sourcing.
Bouvette CA, Bouvette M, Yohannan B, Rumman A, Ali I. Bouvette CA, et al. Am J Gastroenterol. 2024 Apr 1;119(4):764-767. doi: 10.14309/ajg.0000000000002625. Epub 2023 Dec 12. Am J Gastroenterol. 2024. PMID: 38084855
Impact of U.S. federal and state generic drug policies on drug use, spending, and patient outcomes: A systematic review.
Mishuk AU, Fasina I, Qian J. Mishuk AU, et al. Res Social Adm Pharm. 2020 Jun;16(6):736-745. doi: 10.1016/j.sapharm.2019.08.031. Epub 2019 Aug 17. Res Social Adm Pharm. 2020. PMID: 31445986 Review.
Medications Cost Resources.
Bristow AS, Jones LM, Bruce RT, Grant JS. Bristow AS, et al. Home Healthc Now. 2023 Sep-Oct 01;41(5):263-265. doi: 10.1097/NHH.0000000000001189. Home Healthc Now. 2023. PMID: 37682739 Review.

See all similar articles

Cited by

Costs and Access Barriers to Ondansetron in the US.
Jiang C, Yabroff KR, Nipp RD, Han X, Hu X, Liao JM, Shih YT. Jiang C, et al. JAMA Netw Open. 2024 Nov 4;7(11):e2443978. doi: 10.1001/jamanetworkopen.2024.43978. JAMA Netw Open. 2024. PMID: 39509134 Free PMC article.
Drug Pricing Stewardship from Mark Cuban's Cost Plus Generic Drug Program.
Gulati S, Gupta M, Yan T, Yelamanchili S, Xu LQ, Bharani T, Naji A, Agarwal D. Gulati S, et al. Pharmacoeconomics. 2024 Nov;42(11):1279-1286. doi: 10.1007/s40273-024-01426-3. Epub 2024 Aug 21. Pharmacoeconomics. 2024. PMID: 39167355
Patient-Level Savings on Generic Drugs Through the Mark Cuban Cost Plus Drug Company.
Kouzy R, El Alam MB, Corrigan KL, Lalani HS, Ludmir EB. Kouzy R, et al. JAMA Health Forum. 2024 Jun 7;5(6):e241468. doi: 10.1001/jamahealthforum.2024.1468. JAMA Health Forum. 2024. PMID: 38874962 Free PMC article.
Direct-to-Consumer Pharmacies: Disruptive Innovation or More Complexity?
Gupta R. Gupta R. J Gen Intern Med. 2024 Sep;39(12):2131-2132. doi: 10.1007/s11606-024-08729-3. J Gen Intern Med. 2024. PMID: 38671201 No abstract available.
Availability and Cost of Expensive and Common Generic Prescription Drugs: A Cross-sectional Analysis of Direct-to-Consumer Pharmacies.
Lalani HS, Tessema FA, Kesselheim AS, Rome BN. Lalani HS, et al. J Gen Intern Med. 2024 Sep;39(12):2187-2195. doi: 10.1007/s11606-024-08623-y. Epub 2024 Feb 6. J Gen Intern Med. 2024. PMID: 38321315

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information